ED
RXII

Exane Derivatives’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Exane Derivatives’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-100,000
Closed -$151K – 580
2014
Q4 		$151K Buy
+100,000
New +$151K 0.02% 246

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Exane Derivatives's RXII Position: Q1 2015 in Review

Exane Derivatives sold out of GALENA BIOPHARMA INC COM (RXII) in Q1 2015, closing a stake of 100,000 shares — an estimated $151K sold.

Exane Derivatives first reported a position in RXII in Q4 2014 and held it in 1 quarter. The position peaked at $151K in Q4 2014. 87 funds tracked by Wall St. Rank hold RXII as of Q1 2015.

  • Exane Derivatives reported no remaining GALENA BIOPHARMA INC COM position as of Q1 2015 after selling out during the quarter.
  • Exane Derivatives sold 100,000 GALENA BIOPHARMA INC COM shares in Q1 2015, an estimated $151K.
  • Exane Derivatives first reported a position in GALENA BIOPHARMA INC COM in Q4 2014 and held it in 1 quarter.
  • Exane Derivatives's GALENA BIOPHARMA INC COM position peaked at $151K in Q4 2014.
  • 87 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q1 2015.

Based on Exane Derivatives's 13F filing for Q1 2015, filed 15 May 2015.